With potential to revolutionize tissue immunostaining
Picture of UCNP-stained HER2 marker in breast tissue. The colour is easily digitally edited after the image capture, which makes it possible to highlight interesting areas in each sample. The colours of the markers are digitally edited after the image capture. Lumito’s advisors in the field of pathology have now had the opportunity to review […]
New CEO of Lumito AB
The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021. The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021. Mattias Lundin is currently the […]
Quarterly report 3, 2020, Lumito AB (publ)
Financial overview of the third quarter July 1st – September 30th, 2020 Net sales amounted to SEK 0 (0) thousand. Profit after tax amounted to SEK -3,851 (-1,325) thousand. Earnings per share before and after dilution amounted to SEK -0.05 (-0.02). Cash flow from operating activities amounted to SEK -3,850 (-1,325) thousand. Nine months, January […]
Lumito initiates process to engage in dialogue with future partners
The awareness about Lumito's (https://lumito.se/en/home/) potential is on the rise among companies active in digital pathology, and Lumito has received approaches from leading companies in health technologies and diagnostics. The interest in the Company demonstrates that Lumito is in just the right phase. Diagnostics is currently a bottleneck of the system. More and more laboratories abandon […]
Two European patents approved for tissue diagnostics
"Another milestone is passed as Lumito's third patent family now is granted in Europe as the first region. The patent (WO2018224688A1), ”A method of anaIysing a sampIe for at Ieast one anaIyte”, specifically contains the area of application that Lumito's first product launch is targetingand protects the Company's in vitro diagnostics based on upconversion nanoparticles (UCNP). We hope that […]
Stefan Nilsson, CEO of Lumito, has passed away
"It is with great sadness that we announce this tragic and highly unexpected message," says Masoud Khayyami, Chairman of the Board of Lumito. “Stefan Nilsson has left us very unexpectedly. He passed away yesterday due to a heart attack, in connection with exercise on Friday. Our thoughts go to Stefan's family and loved ones.” “With […]
The need for better diagnostic reliability is great and immediate, and Lumito has a solution with potential
These are the words of Björn Isfoss, Chief Pathologist and advisor to Lumito. The cooperation is fully in line with Lumito's strategy to build its own organization with the skills and capacity to manage and develop the current and future products. – I have chosen to work together with Lumito, whose technology has the capacity to meet […]
Delivery from RISE – Lumito proceeds to make optimizations on its own account
On behalf of Lumito, RISE has developed protocols for development of reagents for tissue staining based on UCNPs (UpConverting NanoParticles). The stained tissue samples are scanned with Lumitos scanner to obtain high-contrast imaging without background information. RISE delivered the results of the development effort at the end of June. During spring, Lumito has established a laboratory […]
Lumitos latest presentation and podcast
Stefan Nilsson, the CEO of Lumito, presents the company in Småbolagspodden today and in Aktiedagen yesterday. Both presentations are now available in Swedish at https://lumito.se/presentationer/. Enjoy! Best regards, The Lumito Team For further information, please contact Stefan Nilsson, CEO of Lumito Telephone: +4676-778 59 05 E-mail:sn@lumito.se Latest podcast and presentation
Quarterly report 1, 2020, Lumito AB (publ).
Financial overview of the first quarter, 1 January – 31 March 2020 Result after taxes amounted to kSEK -2,795 (-1,958). Basic and diluted earnings per share amounted to SEK -0.04 (-0.08). Cash flow from operating activities amounted to kSEK -2,793 (-1,958). Cash and cash equivalents amounted to kSEK 17,675 (8,079) on the balance sheet date. […]
